Introduction
Single-unit red blood cell (RBC) transfusions were extensively criticized in the past. It was believed that RBC transfusions were useless if the transfusion requirements could be satisfied by infusion of one RBC unit and that patients were no more in need of the transfusion than their donors [1] [2] [3] . However, data on the risk or benefit of a single-unit transfusion strategy is scarce and most evidence derives from studies analyzing perioperative single-unit RBC transfusions in surgical and obstetrical populations [3] [4] [5] [6] [7] . The essential problem of all these studies is that they introduced a considerable selection bias by simply comparing the pretransfusion hemoglobin levels and the transfusion requirements of patients having received one or two RBC units. Not surprisingly, these studies showed that patients with single-unit transfusions had higher or even normal pretransfusion hemoglobin levels when compared to those receiving double-unit transfusions, and for the vast majority of these single-unit transfusions todays guidelines would not have recommended RBC transfusions at all. However, no study has evaluated the effect of double-or singleunit RBC transfusion in patients with hyporegenerative anemia with comparable pretransfusion hemoglobin levels and there is no evidence supporting double-unit RBC transfusions in patients without active bleeding.
A restrictive transfusion policy with stringent transfusion triggers and a cautious use of blood products is the single most effective measure to reduce transfusion requirements and given the scarcity and inherent risks of allogeneic blood products a reduction of blood transfusions is of major health and economic interest.
Reducing the volume per transfusion may save a considerable number of RBC units thereby reducing the patients' exposure to allogeneic blood products 8 . However, despite a lack of studies, most guidelines recommend double-unit transfusions, while only few more recent guidelines allow single-unit RBC transfusions in the absence of active bleeding [9] [10] [11] [12] [13] [14] . Nonetheless, surveys on transfusion practices have shown that more than 90% of the physicians currently transfuse two RBC units simultaneously showing that they have not yet implemented this new transfusion policy [15] [16] [17] [18] .
Since data suggest that single-unit transfusions may considerably reduce the total RBC requirements we changed our policy for hospitalized patients without active bleeding from double-to single-unit RBC transfusions. The current study analyzed the effect of the new RBC transfusion policy with regards to the overall RBC requirements and the transfusion efficiency, the adherence to the transfusion policy, as well as safety aspects including the bleeding risk and the number of transfused platelets.
Design and Methods

Study population and protocol
This single-center study was performed in the leukemia and the hematopoietic stem cell transplantation units of the University Hospital Zurich. Patients were eligible if they were older or equal to 16 years, received intensive chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation for hematological malignancies and were treated as inpatients. Patients with AML were treated according to the HOVON 42 protocol and patients with acute promyelocytic leukemia according to the APL 2000 study 19, 20 . Allogeneic hematopoietic stem cell transplantation was performed in a laminar flow unit using standard myeloablative-and nonmyeloablative conditioning regimens. Patients receiving chemotherapies predominantly as outpatients were excluded from the study. The local ethical committee approved the study and waived the requirement for written informed consent due to the retrospective nature of the study.
In 2008 we changed our RBC transfusion policy by dispensing only one RBC unit at the time from the blood bank. The single-unit transfusion policy was established in all hospital wards with the exception of the intensive care units, the emergency wards and the operating rooms. More than one RBC unit was dispensed only if explicitly prescribed by the treating physician (e.g. in cases with active bleeding Platelets were transfused as previously described 21 . All platelet units were leukocyte-reduced by means of filtration before storage and contained ≥2.5x10 11 platelets. All patients with morning platelet counts ≤5x10 9 /L received prophylactic platelet transfusions irrespective of bleeding signs. In case of fever or during HSCT, the platelet transfusion trigger was ≤10x10 9 /L. There was no change of the platelet transfusion policy in the two periods.
Measurements and definitions
We analyzed the reduction in the total number of RBC units per therapy cycle and per day of aplasia as well as determinants related to transfusion efficiency and safety, i.e. the number of platelet transfusions, bleeding incidence, outpatient RBC transfusions, the overall survival and adherence to transfusion policy. 
Statistical analysis
Baseline characteristics are displayed as proportions or medians with interquartile ranges (IQR). Patients with double-and single-unit RBC transfusions
were compared using Mann-Whitney-U test for continuous variables or chi-squared test for categorical data, as appropriate. To evaluate the independent association between the transfusion policy and the number of RBC units/therapy we applied multiple linear regression modelling. We controlled for the aplasia time during a therapy cycle as important determinant for the total requirement of RBC units and other potential confounders such as patients' age at diagnosis, and hemoglobin levels prior to transfusion and the proportion of irradiated RBC units. The model was further adjusted for the clustering of the data (i.e. repeated procedures in the same patients) by applying robust standard errors 22 .
The overall survival was calculated from the beginning of the chemotherapy or the day of HSCT until death or last follow-up. The survival observation of patients receiving more than one therapy cycle was censored at the beginning of the next cycle. Survival differences between the two transfusion policy groups were estimated with the method of Kaplan and Meier and compared by log rank test as well as by using multivariate stepwise Cox regression analysis further controlling for potential confounders. All reported p-values are two-sided, and p<0.05 were assumed to be statistically significant.
Results
Baseline characteristics
The During one transfusion the median number of RBC units administered was 2 (IQR: 1-2) in the double-and 1 (IQR: 1-2) in the single-unit period (p<0.001). To avoid a selection bias, this analysis also included all transfusions given to patients in the intensive care unit and the operation room (n=133, 9%), while there were no transfusions in the emergency ward. However, as shown in Table 2 (table 3) . As expected, increasing aplasia time was associated with higher RBC transfusion requirements, while the gender and age of the recipients, irradiation of the RBC as well as the haemoglobin levels prior to transfusion did not influence the transfusion requirements.
RBC transfusions
Adherence to the single-unit RBC transfusion policy
Adherence to the assigned RBC transfusion strategy was analyzed by 
RBC transfusion triggers
The RBC transfusion trigger in hospitalized patients was ≤ 60g/L in the absence of anemia symptoms during both periods. A total of 567 (37%) RBC transfusions were given in patients with morning hemoglobin levels lower or equal to 
Safety of single-unit RBC transfusions
The lower hemoglobin levels may result in a higher bleeding risk due to altered rheological properties in severely anemic patients. To exclude this, we analyzed the bleeding episodes in the two cohorts and the total number of transfused platelets.
Severe bleedings occurred in 18 therapy cycles. During these cycles 213 RBC units were administered which equals 14% of the total RBC units. There was no significant difference in the number of therapy cycles with severe bleeding episodes in the double-unit period (7, 5.2%) and single-unit period (11, 8 .0%, p=0.362) and the median number of platelets transfused per therapy cycle was 5 (2-9) and 5 (3-9) in the double-and single-unit period (0.896).
Finally, as shown in figure 3 , we evaluated the overall survival as a measure for safety after chemotherapy and HSCT. Patients receiving more than one therapy cycle were censored at the time of the next cycle. The median observation time was 78 (9-1087) days. The 30-and 100-day survival probability was 98% (95%-confidence interval 96-99%) and 89% (84-94%) without differences between the two groups (p=0.893) indicating that the transfusion policy had no influence on the overall survival.
Discussion
Our retrospective cohort study demonstrates for the first time that a change from double-to single-unit RBC transfusion policy is safe and associated with a reduction of 25% of RBC transfusion requirements in a population with hematooncological disorders. This finding demonstrates that the long-standing dogma that two RBC units are necessary for an adequate hemoglobin increase has to be critically revised.
Although each year over 75 million units of blood are transfused worldwide, both the optimal number of RBC units per transfusion and the best RBC transfusion trigger remain controversial 11 . As a consequence, physicians have to rely primarily on clinical experience rather than published data for their decision-making. In the last decades, the general recommendation was to give two RBC units simultaneously, while single-unit RBC transfusions were discredited as useless [1] [2] [3] and some authors even suggested to critically revise the local transfusion program if more than 50% of the RBC transfusions were given as single-units 23 .
However, this was mainly based on few studies specifically analyzing the effect of single-unit transfusions. The main findings of these studies were that in surgical or obstetric units approximately 25% of all transfusions were single-units.
However, over 50% of all patients received single-unit transfusions at hemoglobin levels >100g/L and approximately 80% of all transfusions were judged to be questionable or not indicated [5] [6] [7] . The studies share several limitations: i) they were performed several decades ago, when the transfusion practices as well as the blood products considerably differed from today's transfusion technologies. ii) All studies analyzed single-unit RBC transfusion by comparing patients having received one or two RBC units without clear transfusion guidelines. In the vast majority of patients receiving only one RBC unit the transfusions were indeed not indicated because the analyzed single-unit RBC transfusions in a non-surgical population.
In contrast, a single-center analysis found that almost 50% of all transfusions were given as single-units, 62% of which were indicated 24 . They concluded that it would be an error to give two units, if one unit is sufficient to correct anemia. One more recent study theoretically analyzed the effect of transfusing only one RBC unit at the time concluding that a single-unit RBC transfusion strategy has a considerable potential to save RBC units and that this was more pronounced when applying lower transfusion triggers 8 . Our current study analyzed for the first time two cohorts of patients who were subjected to either transfusion policy, thus avoiding the selection bias of earlier studies. The limitations of the study are the retrospective single-center analysis, the lack of standardized bleeding assessments and the lack of a quality of life assessment of the patients during the therapy.
Some studies have suggested that a lower hematocrit in the peripheral blood is associated with a poorer marginalization of the circulating platelets and consequently with an increased bleeding risk 15 . Thus, one major concern at the time of changing the transfusion policy in our institution was an increased risk for major bleedings and higher platelet transfusion requirements. Our data, however, reveal no evidence for higher bleeding rates or higher platelet requirements in the single-unit transfusion group.
Moreover, some concerned the higher workload for the health care professionals due to a more frequent transport of RBC units from the local blood bank. It is difficult to assess the exact costs of this blood transport. Indeed, the time between two RBC transfusions was approximately 20% shorter during the single-unit period leading to a higher transfusion frequency and potentially to a higher workload of the health care professionals. However, it is not clear whether the reduced workload due to fewer transfusions outweighs the workload of the blood transport.
And even if the workload is moderately increased, we believe that the higher workload is justified given the inherent risk of each blood transfusion and the hospital logistics for blood supply should be improved rather than giving unnecessary blood transfusions to patients.
As for the workload, it is difficult to provide exact data on the real costs of transfusions of blood products. A recently published study meticulously analyzed the real costs of RBC transfusion in four hospitals 25 . In this study, an activity-based 26 . In patients with hemato-oncological disorders only limited data exist regarding the optimal transfusion threshold 34 . In patients receiving intensive chemotherapies for AML the requirements differed considerably between centers and a more restrictive transfusion threshold seems to be feasible in these patients 35, 36 .
An interesting finding of our study shows that the hemoglobin levels directly before transfusion of RBC were slightly lower during the single unit period despite similar transfusion guidelines in the two periods. Likewise, the hemoglobin levels at the time of discharge were slightly lower, but this difference did not translate into a higher transfusion rate as outpatients. These findings may indicate that anemia during transfusion dependency is better tolerated in the absence of large fluctuations between the peak and trough hemoglobin caused by the administration of 2 RBC units. In the situation of fewer clinical symptoms the patients may also better tolerate the lower transfusion threshold. It seems rather unlikely that more patients suffered from fatigue and anemia symptoms during the single-unit period, since these symptoms were considered as transfusion triggers throughout the study duration.
However, we did not perform a proper assessment of the fatigue and the quality of life and therefore we cannot draw definite conclusions.
In conclusion, this is the first study indicating that a change to a single-unit transfusion policy can safely reduce the RBC transfusion requirements by approximately 25% without changing the transfusion triggers. Our data suggest that a single-unit RBC transfusion policy is effective and cost saving and is not associated with an increased risk for the patients, but with a moderately elevated workload for the health care professionals. Given the scarceness of allogeneic blood products and the inherent risk of all blood transfusions, these results may have a major impact in the transfusion strategies for patients with hyporegenerative anemias. These data have to be confirmed in prospective randomized trials. Kaplan-Meier survival estimates in patients during the double-and single-unit RBC period. The 30-and 100-day survival probability was 98% (95%-confidence interval 96-99%) and 89% (84-94%) without differences between the two groups (p=0.893) indicating that the transfusion policy had no influence on the overall survival. 
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